These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
64 related articles for article (PubMed ID: 25264963)
41. Cognitive dysfunction in depression - pathophysiology and novel targets. Carvalho AF; Miskowiak KK; Hyphantis TN; Kohler CA; Alves GS; Bortolato B; G Sales PM; Machado-Vieira R; Berk M; McIntyre RS CNS Neurol Disord Drug Targets; 2014; 13(10):1819-35. PubMed ID: 25470397 [TBL] [Abstract][Full Text] [Related]
42. Pharmacotherapy of trichotillomania (hair pulling disorder): an updated systematic review. Rothbart R; Stein DJ Expert Opin Pharmacother; 2014 Dec; 15(18):2709-19. PubMed ID: 25399534 [TBL] [Abstract][Full Text] [Related]
43. The Potential of N-Acetyl-L-Cysteine (NAC) in the Treatment of Psychiatric Disorders. Bradlow RCJ; Berk M; Kalivas PW; Back SE; Kanaan RA CNS Drugs; 2022 May; 36(5):451-482. PubMed ID: 35316513 [TBL] [Abstract][Full Text] [Related]
44. Glutamatergic dysfunction in skin-picking disorder: treatment of a pediatric patient with N-acetylcysteine. Percinel I; Yazici KU J Clin Psychopharmacol; 2014 Dec; 34(6):772-4. PubMed ID: 25203471 [No Abstract] [Full Text] [Related]
45. [Topiramate augmentation in treatment-resistant obsessive-compulsive disorder]. Vinkers DJ; van der Wee NJ Tijdschr Psychiatr; 2008; 50(11):747-50. PubMed ID: 18991236 [TBL] [Abstract][Full Text] [Related]
46. Lack of efficacy of low doses of quetiapine addition in refractory obsessive-compulsive disorder. Sevincok L; Topuz A J Clin Psychopharmacol; 2003 Oct; 23(5):448-50. PubMed ID: 14520120 [TBL] [Abstract][Full Text] [Related]
47. The promise of N-acetylcysteine in the treatment of obsessive-compulsive disorder. Carollo M; Carollo N; Montan G CNS Neurosci Ther; 2024 Feb; 30(2):e14653. PubMed ID: 38385640 [No Abstract] [Full Text] [Related]
48. Buspirone augmentation of fluoxetine in patients with obsessive compulsive disorder. Jenike MA; Baer L; Buttolph L J Clin Psychiatry; 1991 Jan; 52(1):13-4. PubMed ID: 1988411 [TBL] [Abstract][Full Text] [Related]
49. The role of glutamatergic dysfunction in treatment-resistant obsessive-compulsive disorder: treatment of an adolescent case with N-acetylcysteine augmentation. Yazici KU; Percinel I J Child Adolesc Psychopharmacol; 2014 Nov; 24(9):525-7. PubMed ID: 25264963 [No Abstract] [Full Text] [Related]
50. Glutamatergic dysfunction--newer targets for anti-obsessional drugs. Bhattacharyya S; Chakraborty K Recent Pat CNS Drug Discov; 2007 Jan; 2(1):47-55. PubMed ID: 18221217 [TBL] [Abstract][Full Text] [Related]
51. Glutamatergic Agents in the Treatment of Compulsivity and Impulsivity in Child and Adolescent Psychiatry: a Systematic Review of the Literature. Mechler K; Häge A; Schweinfurth N; Glennon JC; Dijkhuizen RM; Murphy D; Durston S; Williams S; K Buitelaar J; Banaschewski T; Dittmann RW; Tactics Consortium T Z Kinder Jugendpsychiatr Psychother; 2018 May; 46(3):246-263. PubMed ID: 28922069 [TBL] [Abstract][Full Text] [Related]
52. N-Acetyl Cysteine and Vitamin D Supplementation in Treatment Resistant Obsessive-compulsive Disorder Patients: A General Review. di Michele F; Siracusano A; Talamo A; Niolu C Curr Pharm Des; 2018; 24(17):1832-1838. PubMed ID: 29663874 [TBL] [Abstract][Full Text] [Related]
53. Oral acetylcysteine for neuropsychiatric disorders. Racz R; Sweet BV; Sohoni P Am J Health Syst Pharm; 2015 Jun; 72(11):923-6, 928-9. PubMed ID: 25987686 [No Abstract] [Full Text] [Related]